DiaMedica Therapeutics (DMAC) Accounts Payables (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Accounts Payables for 10 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 123.0% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (up 123.0% YoY), and the FY2025 full-year result was $1.5 million, up 56.91% from the prior year.
• Accounts Payables declined to $2.8 million in Q2 2026 per DMAC's latest filing, from $3.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $3.3 million in Q1 2026 and bottomed at $433000.0 in Q1 2022.
• Historically, Accounts Payables has averaged $1.3 million across 5 years, with a median of $933000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables surged 311.09% in 2023, then sank 59.78% in 2024.
• Over 5 years, Accounts Payables stood at $734000.0 in 2022, then grew by 26.16% to $926000.0 in 2023, then climbed by 1.51% to $940000.0 in 2024, then jumped by 56.91% to $1.5 million in 2025, then surged by 90.64% to $2.8 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $2.8 million, $3.3 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.